Phase 4
N=115
Systemic Steroids for Peripheral Nerve Blocks
Osteoarthritis, Hip
Bottom Line
View on ClinicalTrials.gov: NCT02464176 ↗Enrolled (actual)
115
Serious AEs
0.0%
Results posted
Jan 2018
Primary outcome: Primary: Duration of Sensory Blockade — 18.5; 18.1; 19.6 hours
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Dexamethasone (Drug); Bupivacaine (Drug); Epinephrine (Drug); Lumbar Plexus Nerve Block (Procedure); Saline (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Wake Forest University Health Sciences
- Primary completion
- Jan 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Duration of Sensory Blockade |
18.5; 18.1; 19.6 | — |
| SECONDARY Time to First Analgesic Request |
474; 533; 432 | — |
| SECONDARY Total Opioid Consumption |
36.6; 30; 39.2 | — |
| SECONDARY Verbal Numeric Pain Score Comparisons |
3; 2; 3 | — |
Summary
This study will investigate the ability of systemic dexamethasone to prolong the sensory block duration for lumbar plexus nerve blockade.
Eligibility Criteria
Inclusion Criteria: Primary elective total hip arthroplasty surgery
- must be a candidate for placement of a lumbar plexus block under anatomic landmark technique using electrical stimulation
- must give written informed consent for anesthesia
- must also be reliable and able to give accurate verbal pain scores postoperatively
Exclusion Criteria
- contraindications to regional anesthesia including, allergy to amide local anesthetics, presence of peripheral neurologic dysfunction, pre-existing coagulopathy or infection in the area of interest will be excluded.
- insulin and non-insulin dependent diabetes mellitus
- preoperative use of systemic corticosteroids within 30 days of surgery
- chronic opioid use (defined as daily opioid dose of greater than 40 mg of oxycodone equivalents or any long-acting opioid)
- pregnancy
- failure to effectively place the lumbar plexus block.
- known prior adverse reaction to dexamethasone (for example: psychosis) or an allergy to dexamethasone
Data sourced from ClinicalTrials.gov (NCT02464176). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.